<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) studies in patients with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> report higher risk of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:mp ids='MP_0006109'>fibrillation</z:mp> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) early post-implant, potentially related to local proarrhythmic effects of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> leads </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To characterize early and long-term risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> discharge for VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> in a large <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> (HCM) cohort </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: By using HCM multicenter registry data, we compared long-term risk of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> subsequent to an early post-implant period (a priori defined as within 3 months of implant) between patients with or without VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> within 3 months after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Over a median follow-up of 4.3 years, 109 of 506 (22%) patients with HCM who received <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> received at least 1 ICD discharge for VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Risk of first <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> discharge for VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> was highest in the first year post-implant (10.8% per person-year; 95% confidence interval 7.9-13.8) and particularly in the first 3 months (17.0% per person-year; 95% confidence interval 9.8-24.3) </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with early VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (≤3 months post-implant) were older, and more commonly had secondary prevention <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> following <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> or systolic dysfunction (end-stage HCM with ejection fraction&lt;50%) </plain></SENT>
<SENT sid="6" pm="."><plain>Only 2 of 247 (0.7%) patients with primary prevention <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> and preserved systolic function had early VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> early post-implant (≤3 months) had more than 5-fold higher risk for future VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> during long-term follow-up compared with patients without early VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (adjusted hazard ratio 5.4; 95% confidence interval 2.3-12.6) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: High-risk patients with HCM and VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> early after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation are particularly prone to subsequent VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> throughout follow-up </plain></SENT>
<SENT sid="9" pm="."><plain>Early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> interventions for VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> are largely confined to patients with prior <z:hpo ids='HP_0001695'>cardiac arrest</z:hpo> or systolic dysfunction and therefore more likely driven by higher arrhythmic risk rather than lead-related proarrhythmia </plain></SENT>
</text></document>